Literature DB >> 15529306

Diagnostic procedures after a positive spiral computed tomography lung carcinoma screen.

Paul F Pinsky1, Pamela M Marcus, Barnett S Kramer, Matthew Freedman, Hrudaya Nath, Paul Kvale, Douglas Reding.   

Abstract

BACKGROUND: Low-radiation dose spiral computed tomography (LDCT) currently is being evaluated as a screening modality for lung carcinoma in a randomized trial. Although several diagnostic algorithms for the workup of positive LDCT screens have been proposed, to the authors' knowledge there is no widely accepted standard to date and there are few nationwide data concerning how such diagnostic workups are actually being performed outside a research protocol setting.
METHODS: The Lung Screening Study (LSS) was a multicenter feasibility trial that randomized 1660 subjects to undergo LDCT and an equivalent number to undergo chest X-ray. Subjects with positive screens were referred to their own health care providers for diagnostic follow-up; LSS did not specify a diagnostic algorithm. LSS collected and abstracted medical records regarding procedures employed in the diagnostic workup of positive screens.
RESULTS: Of the 522 subjects with a positive LDCT screen at baseline or at Year One, 12% underwent biopsy. Biopsy was less likely to be performed in subjects with 4-9-mm nodules (5%) than in subjects with nodules measuring 10+ mm (25%) or in subjects with no nodules but other suspicious findings (15%). Among 63% of the subjects who underwent chest CT on follow-up, the median time between screening and first follow-up chest CT was 82 days. Only a minority of subjects received diagnostic workups that were consistent with published algorithms.
CONCLUSIONS: The data from the current study represent the experience of subjects followed by their health care providers in five different U.S. metropolitan areas and one rural area. As such, they provide some indication of practices in the U.S. with regard to the diagnostic workup of patients with positive spiral CT screens.

Entities:  

Mesh:

Year:  2005        PMID: 15529306     DOI: 10.1002/cncr.20746

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Computed tomography screening for lung cancer.

Authors:  Pamela M McMahon; David C Christiani
Journal:  BMJ       Date:  2007-02-10

Review 2.  Screening for lung cancer using low-dose computed tomography: concerns about the application in low-risk individuals.

Authors:  Jiu-Wei Cui; Wei Li; Fu-Jun Han; Yu-Di Liu
Journal:  Transl Lung Cancer Res       Date:  2015-06

3.  Resource use and guideline concordance in evaluation of pulmonary nodules for cancer: too much and too little care.

Authors:  Renda Soylemez Wiener; Michael K Gould; Christopher G Slatore; Benjamin G Fincke; Lisa M Schwartz; Steven Woloshin
Journal:  JAMA Intern Med       Date:  2014-06       Impact factor: 21.873

4.  Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer.

Authors:  Rachel M Ostroff; William L Bigbee; Wilbur Franklin; Larry Gold; Mike Mehan; York E Miller; Harvey I Pass; William N Rom; Jill M Siegfried; Alex Stewart; Jeffrey J Walker; Joel L Weissfeld; Stephen Williams; Dom Zichi; Edward N Brody
Journal:  PLoS One       Date:  2010-12-07       Impact factor: 3.240

5.  Nanodelivery of MRI contrast agent enhances sensitivity of detection of lung cancer metastases.

Authors:  Matthew Freedman; Esther H Chang; Qi Zhou; Kathleen F Pirollo
Journal:  Acad Radiol       Date:  2009-05       Impact factor: 3.173

6.  The Pittsburgh Lung Screening Study (PLuSS): outcomes within 3 years of a first computed tomography scan.

Authors:  David O Wilson; Joel L Weissfeld; Carl R Fuhrman; Stephen N Fisher; Paula Balogh; Rodney J Landreneau; James D Luketich; Jill M Siegfried
Journal:  Am J Respir Crit Care Med       Date:  2008-07-17       Impact factor: 21.405

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.